- Active not recruitingPHASE3
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
This study is looking at three new medicines for advanced melanoma, a type of skin cancer. It aims to see if combining these medicines helps people with melanoma that has spread and has a specific gene change called 'BRAF'.
For: MelanomaUnited States · Argentina · Austria - RecruitingPHASE1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
This study is testing a new medicine, PF-07799933, for advanced cancers with a specific gene change (BRAF alterations). It aims to see how safe and effective it is, sometimes combined with other medicines, for people when usual treatments haven't worked.
For: Melanoma · Non-Small-Cell Lung Cancer · Thyroid CancerUnited States · Canada · Israel - Active not recruitingPHASE2
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations
This study looks at new drug combinations, binimetinib and encorafenib, for people with advanced cancers. It focuses on specific gene changes (BRAF mutations) that haven't responded to other treatments, aiming to see how well these drugs shrink tumors.
For: Solid TumorCanada - RecruitingPHASE3
Personalized Medicine for Advanced Biliary Cancer Patients
This study looks at whether adding a special "targeted" drug after initial treatment for advanced bile duct cancer works better than continuing standard treatment. It customises treatment based on your tumour's unique features.
For: Biliary Tract NeoplasmsBelgium · France · United Kingdom - Recruiting
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
This study looks at how well two medicines, encorafenib and binimetinib, work together for people with a specific type of advanced melanoma. It also checks on side effects and how it affects quality of life in everyday healthcare, outside of a strict clinical trial setting.
For: Melanoma Stage IV · Melanoma Stage IIIAustria · Germany · Switzerland - RecruitingPHASE1, PHASE2
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
This study looks at a new drug, IDE196, for certain advanced cancers that have specific genetic changes called GNAQ/11 mutations or PRKC fusions. It checks if the drug is safe and effective alone or when combined with other existing cancer drugs.
For: Metastatic Uveal Melanoma · Cutaneous Melanoma · Colorectal CancerUnited States · Australia · Canada